Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment

Zuzana Zakostelska, Miloslav Kverka, Klara Klimesova, Pavel Rossmann, Jakub Mrazek, Jan Kopecny, Michaela Hornova, Dagmar Srutkova, Tomas Hudcovic, Jakub Ridl, Helena Tlaskalova-Hogenova

. 2011 ; 6 (11) : e27961. [pub] 20111122

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12024233

Grant support
NS10340 MZ0 CEP Register

BACKGROUND: Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc) could decrease the severity of intestinal inflammation in a murine model of IBD. METHODOLOGY/PRINCIPAL FINDINGS: The preventive effect of oral administration of Lc significantly reduces the severity of acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluorescence and PCR. We also measured CD4(+)FoxP3(+) regulatory T cells proportion by FACS analysis, microbiota composition by pyrosequencing, and local cytokine production by ELISA. Lc leads to a significant protection against increased intestinal permeability and barrier dysfunction shown by preserved ZO-1 expression. We found that the Lc treatment increases the numbers of CD4(+)FoxP3(+) regulatory T cells in mesenteric lymph nodes (MLN), decreases production of pro-inflammatory cytokines TNF-α and IFN-γ, and anti-inflammatory IL-10 in Peyer's patches and large intestine, and changes the gut microbiota composition. Moreover, Lc treatment prevents lipopolysaccharide-induced TNF-α expression in RAW 264.7 cell line by down-regulating the NF-κB signaling pathway. CONCLUSION/SIGNIFICANCE: Our study provided evidence that even non-living probiotic bacteria can prevent the development of severe forms of intestinal inflammation by strengthening the integrity of intestinal barrier and modulation of gut microenvironment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12024233
003      
CZ-PrNML
005      
20250925111908.0
007      
ta
008      
120815s2011 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0027961 $2 doi
035    __
$a (PubMed)22132181
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jirásková-Zákostelská, Zuzana $7 xx0117342 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
245    10
$a Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment / $c Zuzana Zakostelska, Miloslav Kverka, Klara Klimesova, Pavel Rossmann, Jakub Mrazek, Jan Kopecny, Michaela Hornova, Dagmar Srutkova, Tomas Hudcovic, Jakub Ridl, Helena Tlaskalova-Hogenova
520    9_
$a BACKGROUND: Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc) could decrease the severity of intestinal inflammation in a murine model of IBD. METHODOLOGY/PRINCIPAL FINDINGS: The preventive effect of oral administration of Lc significantly reduces the severity of acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluorescence and PCR. We also measured CD4(+)FoxP3(+) regulatory T cells proportion by FACS analysis, microbiota composition by pyrosequencing, and local cytokine production by ELISA. Lc leads to a significant protection against increased intestinal permeability and barrier dysfunction shown by preserved ZO-1 expression. We found that the Lc treatment increases the numbers of CD4(+)FoxP3(+) regulatory T cells in mesenteric lymph nodes (MLN), decreases production of pro-inflammatory cytokines TNF-α and IFN-γ, and anti-inflammatory IL-10 in Peyer's patches and large intestine, and changes the gut microbiota composition. Moreover, Lc treatment prevents lipopolysaccharide-induced TNF-α expression in RAW 264.7 cell line by down-regulating the NF-κB signaling pathway. CONCLUSION/SIGNIFICANCE: Our study provided evidence that even non-living probiotic bacteria can prevent the development of severe forms of intestinal inflammation by strengthening the integrity of intestinal barrier and modulation of gut microenvironment.
650    _2
$a akutní nemoc $7 D000208
650    _2
$a aplikace orální $7 D000284
650    _2
$a zvířata $7 D000818
650    _2
$a kolitida $x mikrobiologie $x patologie $x patofyziologie $x prevence a kontrola $7 D003092
650    _2
$a trávicí systém $x účinky léků $x mikrobiologie $x patofyziologie $7 D004064
650    _2
$a down regulace $x účinky léků $7 D015536
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunita $x účinky léků $7 D007109
650    _2
$a střevní sliznice $x účinky léků $x imunologie $x mikrobiologie $7 D007413
650    _2
$a Lactobacillus casei $x metabolismus $7 D007780
650    _2
$a lipopolysacharidy $x farmakologie $7 D008070
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a aktivace makrofágů $x účinky léků $7 D008262
650    _2
$a membránové proteiny $x metabolismus $7 D008565
650    _2
$a metagenom $x účinky léků $7 D054892
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední BALB C $7 D008807
650    _2
$a myši SCID $7 D016513
650    _2
$a NF-kappa B $x metabolismus $7 D016328
650    _2
$a permeabilita $x účinky léků $7 D010539
650    _2
$a fosfoproteiny $x metabolismus $7 D010750
650    _2
$a probiotika $x aplikace a dávkování $x farmakologie $7 D019936
650    _2
$a regulační T-lymfocyty $x cytologie $x účinky léků $7 D050378
650    _2
$a TNF-alfa $x biosyntéza $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1#
$a Kverka, Miloslav $7 xx0208988 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Klimešová, Klára $7 xx0128597 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Rossmann, Pavel, $d 1933- $7 jk01102749 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Mrázek, Jakub $u Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Kopečný, Jan $u Institute of Animal Physiology and Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Hornová, Michaela $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic $7 xx0208989
700    1_
$a Šrůtková, Dagmar $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Novy Hradek, Czech Republic $7 xx0335565
700    1#
$a Hudcovic, Tomáš. $7 xx0267225 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Novy Hradek, Czech Republic
700    1_
$a Ridl, Jakub $u Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
700    1_
$a Tlaskalová, Helena, $d 1938- $7 jn20000402365 $u Institute of Microbiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic
773    0_
$w MED00180950 $t PLoS ONE $x 1932-6203 $g Roč. 6, č. 11 (2011), s. e27961
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22132181 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120815 $b ABA008
991    __
$a 20250925111902 $b ABA008
999    __
$a ok $b bmc $g 946381 $s 781561
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 6 $c 11 $d e27961 $e 20111122 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NS10340 $p MZ0
LZP    __
$a Pubmed-20120815/12/02
Back

Find record

Citation metrics

Archiving options